🚀 VC round data is live in beta, check it out!
Faron Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Faron Pharmaceuticals and similar public comparables like Recce Pharmaceuticals, PepGen, Assertio Therapeutics, InflaRx and more.
Faron Pharmaceuticals Overview
About Faron Pharmaceuticals
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested for the prevention of complications that arise from cytokine release syndrome, or hyperinflammatory conditions.
Founded
2006
HQ
Employees
25
Website
Sectors
Financials (LTM)
EV
$132M
Faron Pharmaceuticals Financials
Faron Pharmaceuticals reported last 12-month revenue of $266K and negative EBITDA of ($24M).
In the same LTM period, Faron Pharmaceuticals generated $266K in gross profit, ($24M) in EBITDA losses, and had net loss of ($30M).
Revenue (LTM)
Faron Pharmaceuticals P&L
In the most recent fiscal year, Faron Pharmaceuticals reported revenue of $378K and EBITDA of ($23M).
Faron Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $266K | XXX | $378K | XXX | XXX | XXX |
| Gross Profit | $266K | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($24M) | XXX | ($23M) | XXX | XXX | XXX |
| EBITDA Margin | (8879%) | XXX | (6059%) | XXX | XXX | XXX |
| EBIT Margin | (8733%) | XXX | (5846%) | XXX | XXX | XXX |
| Net Profit | ($30M) | XXX | ($31M) | XXX | XXX | XXX |
| Net Margin | (11228%) | XXX | (8087%) | XXX | XXX | XXX |
| Net Debt | — | — | $14M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Faron Pharmaceuticals Stock Performance
Faron Pharmaceuticals has current market cap of $118M, and enterprise value of $132M.
Market Cap Evolution
Faron Pharmaceuticals' stock price is $0.59.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $132M | $118M | -2.3% | XXX | XXX | XXX | $-0.15 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialFaron Pharmaceuticals Valuation Multiples
Faron Pharmaceuticals trades at 496.0x EV/Revenue multiple, and (5.6x) EV/EBITDA.
EV / Revenue (LTM)
Faron Pharmaceuticals Financial Valuation Multiples
As of April 19, 2026, Faron Pharmaceuticals has market cap of $118M and EV of $132M.
Equity research analysts estimate Faron Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Faron Pharmaceuticals has a P/E ratio of (3.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $118M | XXX | $118M | XXX | XXX | XXX |
| EV (current) | $132M | XXX | $132M | XXX | XXX | XXX |
| EV/Revenue | 496.0x | XXX | 349.3x | XXX | XXX | XXX |
| EV/EBITDA | (5.6x) | XXX | (5.8x) | XXX | XXX | XXX |
| EV/EBIT | (5.7x) | XXX | (6.0x) | XXX | XXX | XXX |
| EV/Gross Profit | 496.0x | XXX | — | XXX | XXX | XXX |
| P/E | (3.9x) | XXX | (3.8x) | XXX | XXX | XXX |
| EV/FCF | (5.6x) | XXX | (6.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Faron Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Faron Pharmaceuticals Margins & Growth Rates
Faron Pharmaceuticals' revenue in the last 12 month declined by (100%).
Faron Pharmaceuticals' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.9M for the same period.
Faron Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (100%) | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Margin | (8879%) | XXX | (6059%) | XXX | XXX | XXX |
| EBITDA Growth | 18% | XXX | 11% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 0% | XXX | 0% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 3113% | XXX | 2338% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 5843% | XXX | 3942% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 5905% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Faron Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Faron Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Recce Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| PepGen | XXX | XXX | XXX | XXX | XXX | XXX |
| Assertio Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| InflaRx | XXX | XXX | XXX | XXX | XXX | XXX |
| Aardvark Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Faron Pharmaceuticals M&A Activity
Faron Pharmaceuticals acquired XXX companies to date.
Last acquisition by Faron Pharmaceuticals was on XXXXXXXX, XXXXX. Faron Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Faron Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialFaron Pharmaceuticals Investment Activity
Faron Pharmaceuticals invested in XXX companies to date.
Faron Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Faron Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Faron Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Faron Pharmaceuticals
| When was Faron Pharmaceuticals founded? | Faron Pharmaceuticals was founded in 2006. |
| Where is Faron Pharmaceuticals headquartered? | Faron Pharmaceuticals is headquartered in Finland. |
| How many employees does Faron Pharmaceuticals have? | As of today, Faron Pharmaceuticals has over 25 employees. |
| Is Faron Pharmaceuticals publicly listed? | Yes, Faron Pharmaceuticals is a public company listed on Nasdaq Helsinki. |
| What is the stock symbol of Faron Pharmaceuticals? | Faron Pharmaceuticals trades under FARON ticker. |
| When did Faron Pharmaceuticals go public? | Faron Pharmaceuticals went public in 2019. |
| Who are competitors of Faron Pharmaceuticals? | Faron Pharmaceuticals main competitors are Recce Pharmaceuticals, PepGen, Assertio Therapeutics, InflaRx. |
| What is the current market cap of Faron Pharmaceuticals? | Faron Pharmaceuticals' current market cap is $118M. |
| What is the current revenue of Faron Pharmaceuticals? | Faron Pharmaceuticals' last 12 months revenue is $266K. |
| What is the current revenue growth of Faron Pharmaceuticals? | Faron Pharmaceuticals revenue growth (NTM/LTM) is (100%). |
| What is the current EV/Revenue multiple of Faron Pharmaceuticals? | Current revenue multiple of Faron Pharmaceuticals is 496.0x. |
| Is Faron Pharmaceuticals profitable? | No, Faron Pharmaceuticals is not profitable. |
| What is the current EBITDA of Faron Pharmaceuticals? | Faron Pharmaceuticals has negative EBITDA and is not profitable. |
| What is Faron Pharmaceuticals' EBITDA margin? | Faron Pharmaceuticals' last 12 months EBITDA margin is (8879%). |
| What is the current EV/EBITDA multiple of Faron Pharmaceuticals? | Current EBITDA multiple of Faron Pharmaceuticals is (5.6x). |
| What is the current FCF of Faron Pharmaceuticals? | Faron Pharmaceuticals' last 12 months FCF is ($24M). |
| What is Faron Pharmaceuticals' FCF margin? | Faron Pharmaceuticals' last 12 months FCF margin is (8830%). |
| What is the current EV/FCF multiple of Faron Pharmaceuticals? | Current FCF multiple of Faron Pharmaceuticals is (5.6x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.